Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASP Isotopes's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASP Isotopes's regulatory disclosures and financial reporting.
ASP Isotopes Inc. (ASPI) announced that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has confidentially submitted a draft registration statement on Form S-1 to the SEC for a proposed initial public offering of QLE’s Class A common stock.
The disclosure was furnished under Item 7.01 (Regulation FD) and, along with the accompanying press release, was issued pursuant to Rule 135. The notice states it does not constitute an offer to sell or a solicitation to buy any securities and will be subject to the registration requirements of the Securities Act.
ASP Isotopes (ASPI) furnished an update on its subsidiary financing. Quantum Leap Energy (QLE), a wholly owned subsidiary, issued an investor presentation and commenced a private placement of QLE convertible promissory notes. QLE entered a definitive purchase agreement for an initial closing of $64.3 million of QLE Notes, led by American Ventures LLC, with ASP Isotopes also making a significant investment. QLE may issue additional notes in subsequent closings to non‑U.S. persons in transactions outside the United States in reliance on Regulation S.
The investor presentation (Exhibit 99.1) and a press release (Exhibit 99.2) are included as exhibits. The information was furnished under Regulation FD and is not deemed filed under the Exchange Act.
ASP Isotopes Inc. (ASPI) reported a corporate update. The company announced that its U.K. subsidiary, Quantum Leap Energy Ltd., has commenced early engagement for regulatory pathways with U.K. nuclear regulators.
The announcement was made via a press release, which is furnished as Exhibit 99.1 and incorporated by reference in this report, other than the fourth and eighth paragraphs of that press release.
ASP Isotopes (ASPI) reported that its subsidiary, Quantum Leap Energy LLC, has completed the purchase of certain assets from One 30 Seven Inc. to advance solutions for processing nuclear waste. The company furnished this update under Item 8.01 and attached a press release as Exhibit 99.1, noting that the ninth paragraph of the release is not incorporated by reference.
ASP Isotopes Inc. (ASPI) launched a primary offering of common stock under an automatic shelf, registering $210,300,405 of shares. The underwriting allocation lists 17,167,380 shares, and the underwriters agreed to purchase at $11.65 per share, yielding approximately $200.0 million in gross proceeds to the company before expenses. Net proceeds are estimated at $199.7 million, with a 30‑day option for up to $31,545,048 of additional shares; if fully exercised, total proceeds before expenses would be about $230.0 million.
The company plans to use proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. ASPI notes recent operating losses and expects existing cash plus the July 2025 raise and this offering to fund operations for more than 12 months from the June 30, 2025 financial statement date. Shares outstanding were 93,406,629 as of October 10, 2025. Underwriter lock-ups apply, and the shares are listed on Nasdaq under “ASPI”.
ASP Isotopes Inc. entered into an underwriting agreement to sell 17,167,380 shares of common stock at $11.65 per share. The underwriters have a 30‑day option to purchase up to 2,575,106 additional shares at the same price.
Gross proceeds are expected to be approximately $210.3 million before underwriting discounts, commissions, and offering expenses. The offering is expected to close on October 16, 2025, subject to customary closing conditions. The sale is being made under the company’s effective Form S‑3 registration statement with a related prospectus and prospectus supplement. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are acting as underwriters.
ASP Isotopes (ASPI) Form 4: Interim CEO and COO reported a sale of 22,500 shares of common stock on 10/14/2025 at a weighted average price of $13.599. The filing states these were “sell to cover” transactions executed under a Rule 10b5‑1 trading plan adopted on June 9, 2025 to cover tax withholding tied to vesting of restricted stock awards.
Trades occurred across multiple executions at prices ranging from $12.31 to $14.46. Following the transactions, the reporting person beneficially owns 1,647,193 shares directly.
ASP Isotopes Inc. (ASPI) launched a preliminary prospectus supplement for a primary underwritten offering of common stock on Nasdaq. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are joint bookrunning managers. The underwriters have a 30‑day option to purchase additional shares. Net proceeds are intended for general corporate purposes, including working capital, operating expenses, and capital expenditures, and may also support complementary acquisitions (with no binding commitments).
ASPI’s stock last closed at $13.32 on October 13, 2025. Shares outstanding were 93,406,629 as of October 10, 2025; this is a baseline figure, not the amount being offered. The company reported $67.7 million in cash and cash equivalents as of June 30, 2025, and raised $56.3 million in net proceeds in July 2025. Lock‑ups apply following closing: company 90 days; executive officers 60 days plus 30 days; directors 30 days plus 30 days, subject to stated exceptions.
ASP Isotopes Inc. reported business updates via Form 8-K. The company announced a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the United States. A press release with details is furnished as Exhibit 99.1.
Todd Wider, a director of ASP Isotopes Inc. (ASPI), executed equity transactions on 09/14/2025 and 09/15/2025. He acquired 96,000 shares through exercise of stock options with a conversion/exercise price of $2, and the reported ownership following that transaction was 806,230 shares. The filing also reports 21,892 shares withheld to satisfy option exercise-related obligations at an average price of $8.77, and a sale of 74,108 shares on 09/15/2025 at a weighted average price of $8.7551, leaving beneficial ownership of 710,230 shares after the reported transactions.